tirzepatide in hfpef patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality compared to sitagliptin, but offered no additional benefit over semaglutide. #ESCCongress Tirzepatide Benefits in Obesity-Related HFpEF

Clinical data consistently shows that tirzepatide produces greater weight loss than semaglutide in head-to-head comparisons

244,245 However, chronic GLP-1-based therapies demonstrated several CV benefits in diabetic patients, as liraglutide and exenatide therapies decreased all-cause mortality

When your brain processes a competing tactile stimulus (toe wiggling), it dedicates fewer processing resources to the injection sensation

Semaglutide (Wegovy) for chronic weight management follows a different escalation: 0.25 mg weekly for four weeks, then 0.5 mg for four weeks, 1 mg for four weeks, 1.7 mg for four weeks, and finally a maintenance dose of 2.4 mg weekly